• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
By KEVIN CURRAN Aug 26, 2019 | 08:49 AM EDT
Stocks quotes in this article: AMGN, CELG, ALXN, BMY, AZN

Amgen Inc.  (AMGN) is adding to its stable of profitable drugs with the announcement that it will acquire the global rights to Celgene Corp.'s (CELG) oral psoriasis treatment Otezla for $13.4 billion in cash as Celgene looks to clear the way for regulators to approve its acquisition by Bristol-Myers Squibb Co. (BMY) .

"The acquisition of Otezla offers a unique opportunity for Amgen to provide patients an innovative oral therapy for psoriasis and psoriatic arthritis that fits squarely within our portfolio and complements our Enbrel and AMGEVITA brands," Amgen CEO Robert Bradway said in a statement. "We will take advantage of our 20 years of experience in inflammatory disease to realize the full global potential of Otezla as an affordable option for patients with these serious, chronic inflammatory conditions."

Otezla currently is the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, which led Amgen management to spend more than half its $21 billion cash pile for the drug.

"Sales of Otezla in 2018 were $1.6 billion, driven by strong volume growth," an Amgen statement said. "Amgen has stated previously that it will focus on medicines that can deliver sustained, long-term volume-driven growth and the company believes there is a significant opportunity to grow Otezla through global expansion and new indications, with expectations for Otezla to realize at least low double-digit sales growth, on average, over the next five years."

Otezla has patent protection until 2028 as well, meaning its profitable status is not under any near-term threat. The deal is expected to close before the end of the calendar year, giving Amgen nearly a decade of patent-protected profits.

Jefferies had noted last week that the deal for Otezla could make sense in light of Amgen's ability to pay in cash, the long-term path and patent protection for Otezla, and Amgen's stated interest in acquiring either drugs or competitors, spurring recent speculation about a possible Alexion Pharmaceuticals (ALXN) deal.

Still, there is some concern about the Otezla purchase as the price Amgen is paying came in well above the expected value of a deal given the necessity for Bristol-Myers Squibb (BMY) to offload the drug and close its own blockbuster takeover of Celgene.

$CELG $BMY to Divest OTEZLA to $AMGN for $13.4 Billion. Much higher than street expected.

— Andy Biotech (@AndyBiotech) August 26, 2019

That hefty price tag is likely accounting for the dichotomous stock moves of the involved parties, with Amgen shares down about 2% before Monday's opening bell while Bristol-Myers saw shares surge around 5% in pre-market tading.

A conference call to explain the transaction is underway. Click here to tune in as analysts ask management about the rationale.

Still, for longer-term shareholders, Jim Cramer's Action Alerts PLUS team noted that there are a number of data points that investors can consider in coming weeks about Amgen, which is a holding of Cramer's Action Alerts PLUS charitable trust.

"Shareholders should mark their calendars for Sept. 8, because that's when management is expected to provide a lung cancer progress update on its AMG 510 compound at the 2019 World Conference on Lung Cancer," the team said. "A few weeks later or Sept. 28, management will give colorectal cancer data to the European Society for Medical Oncology. This compound has blockbuster potential, and many on the Street see it as a $2 billion annual product."

Finally, the team noted that Phase III asthma data related to Amgen's joint effort with AstraZeneca (AZN)  to develop Tezepelumab is due in the second half of 2020, which could coincide with further information on the BiTE antibody construct cancer treatment.

For a look at the full pipeline, click here.

"I feel confident that this cancer program is a winner and you can be in the stock here," Cramer commented on the floor of the New York Stock Exchange late last week.

With that catalyst in mind, the addition of another profitable drug could be a nice bonus as that pipeline progresses, even if the price reaction on Monday morning isn't overly positive.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Mergers and Acquisitions | Credit Ratings | Drug Approvals | Investing | Markets | Stocks | Biotechnology | Pharmaceuticals | Action Alerts PLUS | Analyst Actions | Stock of the Day

More from Stocks

Da or Nyet on McDonald's as It Exits Russia?

Bruce Kamich
May 16, 2022 12:15 PM EDT

Let's check out the charts to see the best course of action for investors.

Inflation Is Killing the Consumer

Bret Jensen
May 16, 2022 12:00 PM EDT

It doesn't take much imagination to see how the average consumer is falling behind and losing substantial buying power.

Is a Stealth Bull Market Developing in These Long-Suffering Sectors?

James "Rev Shark" DePorre
May 16, 2022 11:10 AM EDT

I have my eye on relative strength in groups that have lagged for a very long time.

Is It Time to Jump Back Into Ford? Here's How to Trade It

Stephen Guilfoyle
May 16, 2022 11:00 AM EDT

I do believe that the risk/reward proposition is starting to think about smiling favorably on Ford.

Take One on Take-Two Ahead of Earnings

Bruce Kamich
May 16, 2022 10:49 AM EDT

is the worst priced in?

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:14 PM EDT PAUL PRICE

    A New, Very Scary Movie

  • 08:51 AM EDT PAUL PRICE

    Advice From the Future...

  • 12:20 PM EDT PAUL PRICE

    A Blast From the Past Regarding Bitcoin

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login